<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2013-5-68-74</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-238</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕЧЕНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TREATMENT</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ ТРИМЕТАЗИДИНА МВ НА ПОКАЗАТЕЛИ СУТОЧНОГО МОНИТОРИРОВАНИЯ ЭЛЕКТРОКАРДИОГРАММЫ И ПАРАМЕТРЫ ВАРИАБЕЛЬНОСТИ СЕРДЕЧНОГО РИТМА</article-title><trans-title-group xml:lang="en"><trans-title>TRIMETAZIDINE MR EFFECTS ON THE PARAMETERS OF 24-HOUR ELECTROCARDIOGRAM MONITORING AND HEART RATE VARIABILITY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-кардиолог лаборатории функциональных методов исследования и рациональной фармакотерапии сердечно-сосудистых заболеваний</p></bio><email xlink:type="simple">novikovamv@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глезер</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Glezer</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>профессор кафедры профилактической и неотложной кардиологии ФППОВ, зав.лабораторией функциональных методов исследования рациональной фармактерапии сердечно-сосудистых заболеваний НИЦ</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ Городская клиническая больница № 59 ДЗ г. Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow City Healthcare Department, City Clinical Hospital No. 59</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ Городская клиническая больница № 59 ДЗ г. Москвы; &#13;
ГБОУ Первый Московский государственный медицинский университет имени И.М. Сеченова, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow City Healthcare Department, City Clinical Hospital No. 59; &#13;
I.M. Sechenov First Moscow State Medical University, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2013</year></pub-date><volume>12</volume><issue>5</issue><fpage>68</fpage><lpage>74</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Новикова М.В., Глезер М.Г., 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="ru">Новикова М.В., Глезер М.Г.</copyright-holder><copyright-holder xml:lang="en">Novikova M.V., Glezer M.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/238">https://cardiovascular.elpub.ru/jour/article/view/238</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить влияние 4-месячной терапии триметазидином МВ на параметры суточного мониторирования (СМ) электрокардиограммы (ЭКГ) и вариабельность сердечного ритма (ВСР) у пациентов со стабильной ишемической болезнью сердца (ИБС).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В рамках простого, проспективного, нерандомизированного исследования с последовательным включением 66 пациентов со стабильной ИБС и стабильным нагрузочным тестом изучали влияние терапии триметазидином МВ на показатели СМ ЭКГ и ВРС.</p></sec><sec><title>Результаты</title><p>Результаты. Триметазидин МВ не оказывал существенного влияния на частоту сердечных сокращений как в среднем за сут, так и в дневные или ночные часы. При лечении не выявлено значимых изменений в частотных и временных параметрах ВСР, и изменений в частоте нарушений ритма сердца. Однако значимо уменьшались число пациентов с депрессиями сегмента ST — с 66,7% до 43,8% (р&lt;0,001) и продолжительность эпизодов ишемии с 10 (6,2;21) до 7,42 (5;12,3) мин (р=0,025).</p></sec><sec><title>Заключение</title><p>Заключение. Включение триметазидина МВ в терапию у пациентов со стабильной ИБС позволяет получить дополнительный положительный противоишемический эффект.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To assess the effects of the four-month trimetazidine MR therapy on the parameters of 24-hour electrocardiogram (ECG) monitoring and heart rate variability (HRV) in patients with stable coronary heart disease (CHD).</p></sec><sec><title>Material and methods</title><p>Material and methods. This prospective, non-randomised study, with the inclusion of 66 consecutive patients who had stable CHD and stable stress test results, investigated the effects of trimetazidine MR therapy on the parameters of 24-hour ECG monitoring and HRV.</p></sec><sec><title>Results</title><p>Results. Trimetazidine MR did not markedly affect the 24-hour, daytime, or nighttime levels of heart rate. Trimetazidine MR therapy was not associated with any substantial changes in frequency and time-domain HRV parameters or in the incidence of cardiac arrhythmias. However, there was a significant reduction in the number of patients with ST segment depression (from 66,7% to 43,8%; p&lt;0,001) and in the duration of ischemic episodes (from 10 (6,2;21) minutes to 7,42 (5;12,3) minutes (p=0,025)).</p></sec><sec><title>Conclusion</title><p>Conclusion. Adding trimetazidine MR to the treatment of patients with stable CHD provides an additional beneficial antiischemic effect.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>стенокардия</kwd><kwd>ишемия миокарда</kwd><kwd>суточное мониторирование ЭКГ</kwd><kwd>вариабельность сердечного ритма</kwd><kwd>триметазидин МВ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>angina</kwd><kwd>myocardial ischemia</kwd><kwd>24-hour ECG monitoring</kwd><kwd>heart rate variability</kwd><kwd>trimetazidine MR</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gibson CM, Ciaglo LN, Southard MC, et al. Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review. J Thromb Thrombolysis 2007;23 (2):135–45.</mixed-citation><mixed-citation xml:lang="en">Gibson CM, Ciaglo LN, Southard MC, et al. Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review. J Thromb Thrombolysis 2007;23 (2):135–45.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lanza GA, Galeazzi M, Guido V, et al. Additional predictive value of heart rate variability in high-risk patients surviving an acute myocardial infarction. Cardiologia 1999;44 (3):249–53.</mixed-citation><mixed-citation xml:lang="en">Lanza GA, Galeazzi M, Guido V, et al. Additional predictive value of heart rate variability in high-risk patients surviving an acute myocardial infarction. Cardiologia 1999;44 (3):249–53.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Curione M, Lucia P, Proietti E, et al. The heart rate variability indices and the circadian rhythm of the hourly heart rate: 2 prognostic indicators of mortality and malignant ventricular arrhythmias in patients with a myocardial infarct. Cardiologia 1996;41 (12):1175–82.</mixed-citation><mixed-citation xml:lang="en">Curione M, Lucia P, Proietti E, et al. The heart rate variability indices and the circadian rhythm of the hourly heart rate: 2 prognostic indicators of mortality and malignant ventricular arrhythmias in patients with a myocardial infarct. Cardiologia 1996;41 (12):1175–82.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">National guidelines for the diagnosis and treatment of stable angina. Cardiovascular Therapy and Prevention 2008, 7 (6), Annex 4. Russian (Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика 2008; 7 (6), Приложение 4).</mixed-citation><mixed-citation xml:lang="en">National guidelines for the diagnosis and treatment of stable angina. Cardiovascular Therapy and Prevention 2008, 7 (6), Annex 4. Russian (Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика 2008; 7 (6), Приложение 4).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Burger AJ, Kamalesh M, Kumar S, Nesto R. Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina. Pacing Clin Electrophysiol 1996;19 (4 Pt 1):411–7.</mixed-citation><mixed-citation xml:lang="en">Burger AJ, Kamalesh M, Kumar S, Nesto R. Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina. Pacing Clin Electrophysiol 1996;19 (4 Pt 1):411–7.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Q, Lu XN, Sun NL. Effects of Verapamil and Metoprolol on heart rate variability in patients with coronary heart disease. Beijing Da Xue Xue Bao 2007;39 (6):610–3.</mixed-citation><mixed-citation xml:lang="en">Zhang Q, Lu XN, Sun NL. Effects of Verapamil and Metoprolol on heart rate variability in patients with coronary heart disease. Beijing Da Xue Xue Bao 2007;39 (6):610–3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowska B, Jankowska EA, Reczuch K, et al. Abnormal indices of autonomic function are no longer predictors of poor outcome in diabetic patients without neuropathy but with coexisting coronary artery disease who receive optimal pharmacological therapy. Kardiol Pol 2009;67 (12):1325–32.</mixed-citation><mixed-citation xml:lang="en">Ponikowska B, Jankowska EA, Reczuch K, et al. Abnormal indices of autonomic function are no longer predictors of poor outcome in diabetic patients without neuropathy but with coexisting coronary artery disease who receive optimal pharmacological therapy. Kardiol Pol 2009;67 (12):1325–32.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pivatelli FC, Dos Santos MA, Fernandes GB, et al. Sensitivity, specificity and predictive values of linear and nonlinear indices of heart rate variability in stable angina patients. Int Arch Med. 2012;5 (1):31. doi: 10.1186/1755–7682–5–31.</mixed-citation><mixed-citation xml:lang="en">Pivatelli FC, Dos Santos MA, Fernandes GB, et al. Sensitivity, specificity and predictive values of linear and nonlinear indices of heart rate variability in stable angina patients. Int Arch Med. 2012;5 (1):31. doi: 10.1186/1755–7682–5–31.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Björkander I, Forslund L, Ericson M, et al. Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction. Clin Physiol Funct Imaging 2009;29 (3):201–8. doi: 10.1111/j.1475–097X.2009.00857.x.</mixed-citation><mixed-citation xml:lang="en">Björkander I, Forslund L, Ericson M, et al. Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction. Clin Physiol Funct Imaging 2009;29 (3):201–8. doi: 10.1111/j.1475–097X.2009.00857.x.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Deedwania PC. Comparison of the prognostic values of ischemia during daily life and ischemia induced by treadmill exercise testing. Am J Cardiol 1994;73 (6):15B-8.</mixed-citation><mixed-citation xml:lang="en">Deedwania PC. Comparison of the prognostic values of ischemia during daily life and ischemia induced by treadmill exercise testing. Am J Cardiol 1994;73 (6):15B-8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. JACC 1996;28 (1):20–4.</mixed-citation><mixed-citation xml:lang="en">Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. JACC 1996;28 (1):20–4.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Astashkin EI, Glezer MG Pharmacological regulation of the exchange of energy substrates in cardiomyocytes under pathological conditions associated with ischemia Cardiovascular Therapy and Prevention 2006; 5 (7):112–23. Russian (Асташкин Е.И., Глезер М.Г. Фармакологическая регуляция обмена энергетических субстратов в кардиомиоцитах при патологических состояниях, связанных с ишемией. Кардиоваскулярная терапия и профилактика 2006; 5 (7): 112–23).</mixed-citation><mixed-citation xml:lang="en">Astashkin EI, Glezer MG Pharmacological regulation of the exchange of energy substrates in cardiomyocytes under pathological conditions associated with ischemia Cardiovascular Therapy and Prevention 2006; 5 (7):112–23. Russian (Асташкин Е.И., Глезер М.Г. Фармакологическая регуляция обмена энергетических субстратов в кардиомиоцитах при патологических состояниях, связанных с ишемией. Кардиоваскулярная терапия и профилактика 2006; 5 (7): 112–23).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; (4): CD003614.</mixed-citation><mixed-citation xml:lang="en">Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; (4): CD003614.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology 2011;120 (2):59–72.</mixed-citation><mixed-citation xml:lang="en">Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology 2011;120 (2):59–72.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Detry JM, Leclercq PJ. Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 1995;76 (6):8B-11.</mixed-citation><mixed-citation xml:lang="en">Detry JM, Leclercq PJ. Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 1995;76 (6):8B-11.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37 (3):279–88.</mixed-citation><mixed-citation xml:lang="en">Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37 (3):279–88.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Morozova TE, Ivanova EP, Rykova SM. Clinico-economical aspects of application of trimetazidine MB in patients with chronic heart failure and cardiac rhythm disturbances. Kardiologiia 2011;51 (9):35–41. Russian (Морозова Т. Е., Иванова Е. П., Рыкова С. М. Клиникофармакологические аспекты применения триметазидина МВ у пациентов с сердечной недостаточностью и нарушениями ритма сердца. Кардиология 2011;51 (9):35–41).</mixed-citation><mixed-citation xml:lang="en">Morozova TE, Ivanova EP, Rykova SM. Clinico-economical aspects of application of trimetazidine MB in patients with chronic heart failure and cardiac rhythm disturbances. Kardiologiia 2011;51 (9):35–41. Russian (Морозова Т. Е., Иванова Е. П., Рыкова С. М. Клиникофармакологические аспекты применения триметазидина МВ у пациентов с сердечной недостаточностью и нарушениями ритма сердца. Кардиология 2011;51 (9):35–41).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
